Dashboard
1
High Management Efficiency with a high ROE of 11.06%
2
Company has very low debt and has enough cash to service the debt requirements
3
Flat results in May 25
4
With ROE of 11.42%, it has a very attractive valuation with a 2.38 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 137,392 Million (Small Cap)
21.00
NA
0.00%
-0.33
10.49%
2.61
Revenue and Profits:
Net Sales:
7,470 Million
(Quarterly Results - May 2025)
Net Profit:
1,314 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.32%
0%
10.32%
6 Months
18.28%
0%
18.28%
1 Year
-21.26%
0%
-21.26%
2 Years
-34.91%
0%
-34.91%
3 Years
-36.26%
0%
-36.26%
4 Years
-13.44%
0%
-13.44%
5 Years
-44.86%
0%
-44.86%
Mani, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.68%
EBIT Growth (5y)
7.82%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.52
Tax Ratio
25.45%
Dividend Payout Ratio
61.11%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
26.20%
ROE (avg)
11.06%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.38
EV to EBIT
13.00
EV to EBITDA
10.15
EV to Capital Employed
3.12
EV to Sales
3.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
24.02%
ROE (Latest)
11.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Aug 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - May'25 - QoQ
May'25
Nov'24
Change(%)
Net Sales
7,470.00
7,655.00
-2.42%
Operating Profit (PBDIT) excl Other Income
2,609.00
2,678.00
-2.58%
Interest
1.00
1.00
Exceptional Items
0.00
-3.00
100.00%
Consolidate Net Profit
1,314.00
1,598.00
-17.77%
Operating Profit Margin (Excl OI)
262.90%
275.50%
-1.26%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Aug'24
Aug'24
Aug'23
Change(%)
Net Sales
28,513.00
24,488.00
16.44%
Operating Profit (PBDIT) excl Other Income
10,662.00
9,162.00
16.37%
Interest
6.00
4.00
50.00%
Exceptional Items
-70.00
84.00
-183.33%
Consolidate Net Profit
6,286.00
5,953.00
5.59%
Operating Profit Margin (Excl OI)
294.30%
295.90%
-0.16%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2024 is 16.44% vs 19.95% in Aug 2023
Consolidated Net Profit
YoY Growth in year ended Aug 2024 is 5.59% vs 12.53% in Aug 2023
About Mani, Inc. 
Mani, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






